Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma

Authors:
  • DLDiane C. Louie
    Diane C. Louie
  • NPNasser Z. Parsa
    Nasser Z. Parsa
  • CPCarol Portlock
    Carol Portlock
  • BYBihui H. Ye
    Bihui H. Ye
  • FLFlorigio Lista
    Florigio Lista
  • DFDaniel A. Filippa
    Daniel A. Filippa
  • ARAyala Rosenbaum
    Ayala Rosenbaum
  • MLMarc Ladanyi
    Marc Ladanyi
  • SJSuresh Jhanwar
    Suresh Jhanwar

Abstract
About 40 percent of non-Hodgkin's lymphomas are diffuse lymphomas with a large-cell component (DLLC). Current therapy can induce a long-term remission in half the patients with DLLC, but more intensive treatment has the potential to improve outcome, particularly in patients at high risk for treatment failure. Clinical and cytogenetic markers can identify subgroups at high or low risk. Rearrangement of a novel candidate proto-oncogene, bcl-6, is a possible prognostic indicator in DLLC.

This publication has 29 references indexed in Scilit: